Message #19 From:
Stock News Bot Date: September 7, 2005 05:00:00 AM
NEOP News Dutton Associates Announces Investment Opinion: Neoprobe Raised To Strong Speculative Buy Rating By Dutton Associates
EL DORADO HILLS, Calif.--(BUSINESS WIRE)--Sept. 7, 2005--Dutton Associates continues coverage of Neoprobe Corporation (OTCBB:NEOP), raising its rating to Strong Speculative Buy and setting a revised price target of $1.00. The 19-page updated initial report by Dutton senior analyst William R. Prather, R.Ph., M.D. is available at www.jmdutton.com as well as from First Call, Bloomberg, Zacks, Reuters, Knobias, and other leading financial portals.
We are revising our investment rating on the common stock of Neoprobe Corporation from Neutral to Strong Speculative Buy because of our belief that the Company will be announcing an important collaboration for radio-immunoguided surgery (RIGS(R)) sometime within the next two quarters. RIGS is intended to provide surgeons with real-time information that enables them to locate tumor deposits not detectable by conventional methods to assist in a more thorough removal of tumor and to improve the surgical treatment of the patient. The Company's initial market for RIGS is in colorectal cancer. We believe this collaboration announcement has the ability to significantly raise the market value of the Company. This assessment is, in turn, based on our belief that RIGS can be important enough to be able to change the standard of practice in treating patients afflicted with carcinoma of the colon. Our 12-month target price for the common stock of the Company is raised to $1.00.
About Dutton Associates
Dutton Associates is one of the largest independent investment research firms in the U.S. Its 27 senior analysts are primarily CFAs and have expertise in many industries. Dutton Associates provides continuing analyst coverage of over 110 enrolled companies, and its research, estimates, and ratings are carried in all the major databases serving institutions and online investors.
The cost of enrollment in our one-year continuing research program is US $35,000 prepaid for 4 Research Reports, typically published quarterly, and requisite Research Notes. Dutton Associates received $55,000 from the Company for 8 Research Reports with coverage commencing on 7/26/2004. The Firm does not accept any equity compensation. Our principals and analysts are prohibited from owning or trading in securities of covered companies. The views expressed in this research report accurately reflect the analyst's personal views about the subject securities or issuer. Neither the analyst's compensation nor the compensation received by us is in any way related to the specific ratings or views contained in this research report or note. Please read full disclosures and analyst background at www.jmdutton.com before investing.
